Shortened Trastuzumab Administration Does Not Improve DFS in ERBB2+ Breast Cancer
Adjuvant trastuzumab plus concurrent chemotherapy led to inferior DFS outcomes when administered for 9 weeks vs 1 year in ERBB2-positive breast cancer.
Related Articles
Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials
PURPOSEOver the past 15 years, the landscape of early phase clinical trials (EPCTs) has undergone a remarkable expansion in both quantity and intricacy. The proliferation…
Transparency and Consolidation Issues Hamper 340B Program in Cancer Care
Since it’s implementation in 1992, the aim of the 340B Drug Pricing Program has been to offer low-income and underserved patient populations with cancer and…
Preparation is Key to Tackle the Transition from Fellow to Attending Physician
A lymphoma hematologist/oncologist who recently transitioned from a fellow to an attending physician shares his experience with the change and tips for fellows.
Shaking Up Gynecologic Cancer Treatment With Mentorship and Patient-Centric Care
Carol Aghajanian, MD, has stayed at the forefront of innovation in gynecologic oncology—and she credits her patients and their conversations in retaining that role.
Abstracts
Learn more about and submit your abstract to the AACR Annual Meeting 2025, held April 25-30, 2025, in Chicago, Illinois.
Neratinib Joins NCCN Guidelines for HER2-Mutated Cervical Cancer
The NCCN Guidelines have been updated to include neratinib for HER2-mutated recurrent/metastatic cervical cancer in the second line or later.
Key Considerations for the Evolving Treatment Landscape for Relapsed/Refractory Follicular Lymphoma
A panelist discusses how various antibody-drug conjugates, including polatuzumab vedotin, pinatuzumab vedotin, and loncastuximab, have been studied in combination with rituximab for relapsed/refractory follicular lymphoma.…
Community Practice Training During Fellowship Often Falls Short
A hematology fellow discusses findings from 2 surveys he coauthored, which sought to identify gaps in community practice training during hematology/oncology fellowship.
FDA Approves Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors
The FDA has approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult solid tumor nivolumab (Opdivo) indications.
Advancing Cell Therapy Research, Discovery & Innovation : Oncology Times
An abstract is unavailable.
